
NASDAQHealthcareBiotechnology
Latest quote
$3.14
−$0.08 · -2.48%
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Previous close
$3.14
−$0.08 · -2.48%
Regular session · ET · Market data may be delayed.
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Day range
Current $3.14
52-week range
Current $3.14
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
31
Expensive
Sentiment
54
Mixed
Risk
59
Elevated Risk
Momentum
71
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Day range
Current $3.14
52-week range
Current $3.14
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 154.22M USD | 73.28M USD | 27.67M USD | 24.25M USD | 38.4M USD |
| Selling, general, and administrative | 18.27M USD | 17.61M USD | 14.09M USD | 12.28M USD | 12.07M USD |
| Operating expenses | 172.5M USD | 90.89M USD | 41.76M USD | 36.53M USD | 50.47M USD |
| Depreciation and amortization | 350K USD | 318K USD | 311K USD | 318K USD | 326K USD |
| Operating income | −172.5M USD | −90.89M USD | −41.76M USD | −36.53M USD | −50.47M USD |
| Net income | −165.67M USD | −80.6M USD | −36.95M USD | −35.36M USD | −50.64M USD |
Company facts updated Nov 22, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$7.00
122.93% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | May 29, 2020 | 1:12 | — | — |
Effective May 29, 2020
1:12
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM5.57M0.01%71.54B USD0.19%$256.61-2.88%
Vanguard Morningstar Total Stock Market ETFVTI4.17M0.00%689.3B USD0.03%$340.02-3.52%
Fidelity Enhanced Small Cap ETFFESM3.33M0.05%6.74B USD0.28%$41.85-2.49%
iShares Russell 2000 Growth ETFIWO2.04M0.02%12.73B USD0.24%$320.43-3.57%
Vanguard Extended Market ETFVXF1.73M0.00%30.2B USD0.05%$211.44-3.21%
Dimensional - US Small Cap ETFDFAS1.64M0.01%31.24B USD0.30%$74.24-2.48%
iShares Biotechnology ETFIBB1.17M0.01%10.53B USD0.44%$199.54-2.05%
Vanguard Russell 2000 ETFVTWO963.9K0.01%16.8B USD0.06%$103.76-2.76%
iShares Russell 2000 ETFIWM
Vanguard Morningstar Total Stock Market ETFVTI
Fidelity Enhanced Small Cap ETFFESM
iShares Russell 2000 Growth ETFIWO
Vanguard Extended Market ETFVXF
Dimensional - US Small Cap ETFDFAS
iShares Biotechnology ETFIBB
Vanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.